Skip to content

Vaxcyte

US · PCVX #1630 by market cap Listed 2020
55.39 -2.97 -5.09%
Periodic snapshot; not a real-time feed. · 2026-11-20 19:30

Price chart

Pre-market 57.76 -1.03%
After-hours 55.72 +0.60%
73.8245.4255.392026-05-262026-11-20
MA5MA10MA20MA60
— MA5 — MA10 — MA20 — MA60
Reader sentiment Are you bullish or bearish on PCVX?

Anonymous reader poll. Unscientific, not investment advice.

✦ StockVane Quant Insights how this is computed

Quant Sentiment Neutral
  • Recent price momentum is +3.2% on average (3-month/1-year).
  • Main-fund capital flow has been a net outflow over the last 45 sessions.
  • Analyst tilt is Buy.
Quant Technical Outlook Neutral
  • Price is below its 20-day average and below its 60-day average.
  • The 20-day average is above the 60-day average, a short-term uptrend.
Quant Rating, last 30 days B → C

Computed by a StockVane algorithm from historical price, valuation and analyst data - not a person, not a forecast guarantee, and not investment advice.

Factor grades

Ranked against 2848 U.S. stocks StockVane covers.

Last computed: 2026-11-22 08:27 UTC

Data coverage: 4 of 6 factors. Missing data is not a zero score.

Overall B-

The radar needs all six factors. Available grades are shown below.

Valuation N/A

How expensive the stock is versus earnings, sales and its own 5-year history.

Not enough data to grade this factor.

Growth N/A

How fast revenue, profit and free cash flow are compounding.

Not enough data to grade this factor.

Profitability D-

How much profit the business keeps from each dollar of sales and capital.

Return on equity -25.6% Better than 14%
Return on invested capital -28.7% Better than 10%
Momentum B

Recent price strength, skipping the latest month to avoid short-term noise.

3-month return -11.5% Better than 47%
6-month return 17.1% Better than 80%
12-month return (ex latest month) 26.5% Better than 66%
Distance below 52-week high 39.0% Better than 30%
Financial Health B

Balance-sheet strength: leverage, liquidity and interest coverage.

Current ratio 7.9x Better than 91%
Debt to assets 3.9% Better than 82%
Interest coverage -111,741.5x Better than 0%
Analyst View A

What the Street thinks: share of Buy ratings and upside to the average target.

Analysts rating Buy 88.9% Better than 72%
Upside to average target 108.8% Better than 85%

Grades are relative rankings, not forecasts: A+ is the top 5% of the covered stocks on a factor, F the bottom 3%. Valuation is not adjusted for sector. Background recomputation is scheduled every 6 hours; actual computation time is shown above, and source datasets have different reporting dates. Not investment advice or tailored to your financial situation.

Performance

1W -12.59%
1M -16.37%
3M -9.70%
6M +17.43%
YTD +20.05%
1Y +16.19%
3Y +7.74%
5Y +143.90%

Key statistics

Price & volume

Prev close
58.36
Open
57.77
Day range
55.27 - 58.48
Avg price
56.25
Volume
1.91M
Turnover
107.55M
Amplitude
5.50%
52-week range
42.40 - 90.75

Valuation

P/E
-9.84
P/E (TTM)
-6.88
P/B
3.52
EPS
-5.63
Net profit
-891.23M
Net assets
2.49B

Share structure

Market cap
8.77B
Float cap
8.08B
Shares out
158.30M
Float shares
145.89M

Dividend & listing

Dividend (TTM)
0.00
Listing date
2020-06-12
52-week range 27% of range
42.40 90.75

39.0% below the 52-week high

Trading activity

Net capital flow main funds, last 45 sessions

-61.86M net over the window

Short interest

Shares short
15.36M
As of
2026-10-30

Frequently asked questions

What is the current stock price of Vaxcyte (PCVX)?

Vaxcyte last traded at 55.39. This page shows a periodic quote snapshot. Check the displayed quote time.

What is Vaxcyte's market cap?

About 8.77B.

What is the P/E ratio of Vaxcyte?

The trailing twelve-month P/E is -6.88. The Valuation tab shows it against the stock's own five-year range.

Does Vaxcyte pay a dividend?

Vaxcyte does not currently pay a regular dividend.

Is Vaxcyte a buy according to analysts?

The consensus of 9 analysts is a Buy rating, with an average 12-month price target of 115.63, which implies 108.8% upside from the current price. This is not investment advice.

What is Vaxcyte's StockVane Quant Rating?

The StockVane Momentum strategy currently rates Vaxcyte a D (Sell). Below its 200-day average or in the bottom third on momentum — the strategy is out of it. Not investment advice.

Quote time 2026-11-20 19:30:05 · For reference only, not investment advice and not tailored to your situation.

Vaxcyte discussion 0 comments

Add a comment